Zoetis Inc. (NYSE:ZTS) Stock Position Reduced by Gouws Capital LLC

Gouws Capital LLC decreased its stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 11.1% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 18,391 shares of the company's stock after selling 2,285 shares during the quarter. Zoetis comprises 2.1% of Gouws Capital LLC's holdings, making the stock its 17th largest position. Gouws Capital LLC's holdings in Zoetis were worth $2,996,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Atlantic Edge Private Wealth Management LLC raised its stake in shares of Zoetis by 482.8% in the 4th quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company's stock valued at $28,000 after acquiring an additional 140 shares during the period. Darwin Wealth Management LLC purchased a new stake in Zoetis in the third quarter valued at $31,000. First Personal Financial Services purchased a new position in shares of Zoetis during the third quarter worth approximately $33,000. Capital Performance Advisors LLP acquired a new stake in Zoetis during the 3rd quarter worth approximately $33,000. Finally, Dunhill Financial LLC boosted its holdings in shares of Zoetis by 80.6% in the third quarter. Dunhill Financial LLC now owns 168 shares of the company's stock valued at $33,000 after acquiring an additional 75 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company's stock.

Zoetis Stock Performance

NYSE ZTS traded down $2.94 during trading hours on Wednesday, reaching $166.96. The company's stock had a trading volume of 3,667,422 shares, compared to its average volume of 3,280,360. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09. The business has a 50-day simple moving average of $166.57 and a 200 day simple moving average of $176.99. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $200.33. The stock has a market cap of $74.76 billion, a PE ratio of 30.52, a PEG ratio of 2.78 and a beta of 0.94.

Zoetis (NYSE:ZTS - Get Free Report) last released its quarterly earnings data on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.37 by $0.03. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The business had revenue of $2.32 billion during the quarter, compared to analyst estimates of $2.30 billion. Equities research analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be issued a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.20%. The ex-dividend date is Monday, April 21st. Zoetis's dividend payout ratio (DPR) is 36.56%.

Analyst Ratings Changes

A number of research firms have recently issued reports on ZTS. UBS Group began coverage on shares of Zoetis in a research report on Monday, December 9th. They set a "neutral" rating and a $196.00 price target for the company. Piper Sandler lifted their price objective on Zoetis from $200.00 to $205.00 and gave the stock an "overweight" rating in a report on Thursday, February 27th. StockNews.com downgraded Zoetis from a "buy" rating to a "hold" rating in a research report on Tuesday, February 25th. Stifel Nicolaus dropped their price target on Zoetis from $210.00 to $180.00 and set a "buy" rating for the company in a research report on Tuesday, January 7th. Finally, Morgan Stanley decreased their price objective on shares of Zoetis from $243.00 to $238.00 and set an "overweight" rating on the stock in a research report on Friday, February 14th. Two analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, Zoetis has a consensus rating of "Buy" and an average price target of $215.90.

Insider Activity at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the firm's stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total transaction of $55,804.68. Following the transaction, the executive vice president now owns 16,107 shares of the company's stock, valued at approximately $2,757,196.26. This trade represents a 1.98 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 0.16% of the company's stock.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.